News & Trending Money News

Trump Claims Credit for the Steepest Drug Price Drop Since 1963 - But Experts Aren't So Sure

Prescription drug prices fell, but several factors explain why.

340B hospital program and donald trump
Updated Nov. 10, 2026
Fact check checkmark icon Fact checked
Google Logo Add Us On Google info

If lower prescription drug costs will help you lower your financial stress, some genuinely good news arrived in August: Federal data shows prescription drug prices posted their steepest annual decline in more than six decades. While the drop is real, the question of who or what caused it is more complicated, and the debate over the answer has political stakes with the November midterms approaching.

Here is what the data says, what the White House is claiming, what drug-pricing experts are saying instead, and why many patients may not feel the difference in their own wallets.

Now Available: The Definitive Guide to Retirement Income

Many successful investors eventually reach the same moment. The saving is done, the portfolio is built, and the question quietly changes from how much can I grow this to how much can I take out? Get that second question wrong and decades of good investing can come apart in a handful of years.

That is exactly what The Definitive Guide to Retirement Income helps answer.1 It covers what your retirement could actually cost, which income sources are worth using, and the withdrawal math that decides whether the money lasts. It is free today from Fisher Investments. Read More Here ›

What the data actually shows

The Bureau of Labor Statistics' Consumer Price Index report released August 12 found that prescription drug prices fell 0.8% from June to July 2026 on a seasonally adjusted basis and dropped 3.1% over the 12 months ending in July, the steepest year-over-year decline since March 1963.

The report also found:

  • Drug prices have not risen in a single month in 2026 and have fallen in five of the last six months.
  • The broader medicinal drugs index (which includes over-the-counter medications) fell 2.7% over the year, reportedly the largest such drop on record.
  • Over the same period, hospital services rose 5.2%, and physicians' services rose 2.4%.

While the decline is real, the CPI index tracks what pharmacies are paid by insurers and consumers on a transaction basis, not list prices and not individual out-of-pocket costs. More on why that matters below.

The administration's position

The White House moved quickly to claim the data as a political win. "From his Most-Favored-Nations deals to launching TrumpRx, President Trump is delivering real results," White House spokesman Kush Desai posted on X after the report was released. "American patients are winning."

The administration points to three specific initiatives:

  • Most-Favored-Nation pricing deals: The Trump administration negotiated agreements with 26 pharmaceutical manufacturers requiring them to sell drugs at prices comparable to what they charge in other wealthy countries. These 26 drugmakers are also exempt from new pharmaceutical tariffs through January 2029, providing additional incentive to participate.
  • TrumpRx: A White House price-comparison website that connects patients with discounted cash prices for certain drugs. The administration credits it with expanding price transparency and giving patients leverage.
  • Medicare GLP-1 Bridge program: Launched in July 2026, this program allows eligible Medicare beneficiaries to obtain weight-loss drugs including Wegovy, Zepbound, and Foundayo at a net monthly price of $245 with a $50 copay, substantially below retail prices that can run into the thousands of dollars monthly.

What the experts say

Drug-pricing analysts largely agree the decline is significant but say the administration's signature policies probably were not the primary drivers.

Richard Frank, a senior fellow at the Brookings Institution and professor emeritus of health economics at Harvard, told The Washington Post that the Biden-era introduction of Medicare price negotiations was more likely the primary cause. "If I was a betting guy on what mattered most, it would be probably stuff around the Inflation Reduction Act," Frank said.

The IRA context: Congress enacted Medicare's authority to negotiate directly with drug manufacturers in the 2022 Inflation Reduction Act. The first negotiated prices on 10 top-selling drugs took effect January 1, 2026. A second round covering 15 more drugs, including Ozempic and Wegovy, is set to take effect in 2027.

Other factors analysts cite alongside or above the administration's specific policies:

  • Generic and biosimilar competition continues to erode prices on drugs whose patents have expired.
  • The introduction of GLP-1 weight-loss competitors drove price pressure across that whole drug class.
  • Changes in the mix of drugs being purchased shifted the overall average.
  • Most-Favored-Nation deals with manufacturers are recent, and many had not yet taken full effect at the time the CPI measured the decline, making their contribution to the July figures hard to confirm.

Axios reported that TrumpRx likely accounts for part of the decline but is probably not the dominant factor, while also crediting the Eli Lilly and Novo Nordisk deals on GLP-1 drugs as more directly measurable.

No published analysis has quantified how much each factor contributed. The question of credit remains genuinely contested.

Released: The Definitive Guide to Retirement Income

Most people spend their entire working lives focusing on one thing: growing a pile of money. Then they retire and discover the skill they actually need is close to the opposite. Turning that pile into steady income, year after year, through good markets and bad, without ever running out. It may be the least discussed and most consequential transition in personal finance, and plenty of otherwise careful investors walk into it with no real plan.

That is exactly what The Definitive Guide to Retirement Income helps answer.1 It is a free guide from Fisher Investments covering what your retirement will really cost, where the cash flow should come from, and how much you can safely withdraw each year. Learn More Here ›

The crucial caveat: What the index does not measure

Even accepting the 3.1% figure as accurate, there is an important gap between that number and what most patients experience.

The BLS CPI measures transaction prices, meaning what pharmacies are paid by insurers and consumers on sampled purchases. It does not measure list prices, manufacturer rebates, or individual out-of-pocket costs at the pharmacy counter. Those figures move independently and are frequently confused in coverage of drug prices.

Practically speaking, many insured patients pay fixed copays that do not change when transaction prices fall. Patients without insurance, or those in the coverage gap on certain plans, may or may not see the decline reflected in what they actually pay.

Over the same 12 months that drug prices fell 3.1%, hospital services rose 5.2%, and physicians' services rose 2.4%. Total health care costs for most American families are not declining. The drug price drop is a genuine bright spot within a broader picture of rising health expenses.

A headwind already building

There is also a forward-looking concern that the current trend may reverse. Vizient's Spend Management Outlook projects pharmaceutical prices will rise 3.54% in 2027, up 0.7 percentage points from its earlier forecast, and that projection does not yet fully account for new pharmaceutical tariffs.

A 100% tariff on patented drugs and their ingredients from large manufacturers took effect July 31 following a Section 232 national security finding. Generic drugs face a separate escalating tariff schedule beginning August 1. The manufacturers with most-favored-nation deals are exempt through January 2029, but the broader industry is not.

The bottom line

The 3.1% drop in prescription drug prices is the largest since 1963, but how much patients save will depend on their medications, insurance coverage, and out-of-pocket costs.

If you want to transform your savings on health care, watch whether drug prices continue falling and whether insurers pass those savings along through lower copays and premiums.

Up To 5% Cash Back

  • Intro APR on purchases and balance transfers
  • $0 annual fee
  • Apply Now
  • INTRO OFFER: Receive a $200 statement credit when you spend $500 on purchases in your first 3 months of account opening
  • UNLIMITED CASHBACK MATCH: Discover will automatically match all the cash back you’ve earned at the end of your first year! There’s no minimum spending or maximum rewards. You could turn $150 cash back into $300. Click Apply Now to view important rates and disclosures
  • Earn 5% cash back on everyday purchases at different places you shop each quarter, up to the quarterly maximum when you activate. Plus, earn unlimited 1% cash back on all other purchases
  • Redeem cash back for any amount. Every $1 you earn in cash back is $1 you can redeem
  • Rewards don't expire for the life of the account
  • No annual fee and no foreign transaction fee
  • Lock your card in the Mobile app if it’s misplaced, lost, or stolen
  • You're covered by $0 Fraud Liability for unauthorized charges
Discover it® Cash Back
4.7
info

on Issuer's secure website

Read Card Review

Intro Offer

UNLIMITED CASHBACK MATCH: Discover will automatically match all the cash back you’ve earned at the end of your first year! There’s no minimum spending or maximum rewards. You could turn $150 cash back into $300. Click Apply Now to view important rates and disclosures. Plus, receive a $200 statement credit when you spend $500 on purchases in your first 3 months of account opening

Annual Fee

$0

+

Why we like it


Financebuzz logo

Thanks for subscribing!

Please check your email to confirm your subscription.